Today’s top gainers include the company Incyte Corporation (NASDAQ:INCY) which is in the industry Biotechnology, gaining -0.20% today. In the last week its performance is -9.89%, and 15.13% for the past quarter. Currently, Incyte Corporation, INCY has a target price of 94.93, so today’s gain of -0.20% is a significant step towards its target price. The GAP today is therefore -0.16%.
Incyte Corporation (NASDAQ:INCY), has a market cap of 15201.21, and is based in USA. Insider ownership is at 0.50%, and institutional ownership is 99.60%.
At the current price of 81.05, it has a dividend yield of *TBA, and its target price is 94.93. This is with a profit margin of 5.70%, and total debt/equity of 0. Incyte Corporation (NASDAQ:INCY) has a P/E of 384.88, as well as a forward P/E of 61.95.
With a current EPS of 0.21, and a forecasted EPS growth for next year at 2373.58%,Incyte Corporation (NASDAQ:INCY) has had a EPS growth for the past five years at 16.40%. For the next five years EPS growth is projected to be 38.70%.
Performance for the year is -24.30%. Since its IPO date on 11/4/1993, the total performance to date is -25.12%.
Volume today for Incyte Corporation (NASDAQ:INCY), is 856377, while its average volume is 1060.78. Whilst the total gain today was -0.20%, it did have a day high of -12.68%.
Volatility for this week has been at 4.51%, and 3.37% for the month. The 52-week low for Incyte Corporation, INCY has been 47.36%, while the 52-week-high has reached -39.34%.
Looking at its return of investments, which is 6.30%, and its return on assets is 4.90%. Incyte Corporation (NASDAQ:INCY) has an operating margin of 10.90%. With a sales growth of 65.40% quarter over quarter. Bearing in mind that Incyte Corporation, INCY is in the sector Healthcare, its long-term debt/equity is 2.76, and has a current ratio of 4.7 and 4.7 for quick ratio.
So what is the value of Incyte Corporation? Well its PEG is 9.95, and the P/S is 17.72, along with a P/B of 66.57. Meanwhile it has a p/cash of 18.75.